



**FOR IMMEDIATE RELEASE**

**Media     Chris Smith**  
**Contact:   Public Relations & Corporate Communications**  
**Eyetech Pharmaceuticals, Inc.**  
Office: (212) 824-3203  
Mobile: (973) 489-5076  
E-mail: [chris.smith@eyetech.com](mailto:chris.smith@eyetech.com)

**Investor    Glenn Sblendorio**  
**Contact:   Chief Financial Officer**  
**Eyetech Pharmaceuticals, Inc.**  
Office: (212) 824-3121  
E-mail: [glenn.sblendorio@eyetech.com](mailto:glenn.sblendorio@eyetech.com)

**Eyetech Announces Conference Call to Reiterate Confidence  
in Macugen® (pegaptanib sodium injection)**

**New York, NY – May 24, 2005 – Eyetech Pharmaceuticals, Inc. (Nasdaq: EYET)** announced that it will hold a conference call to reiterate its confidence in Macugen and discuss issues presented by a potential competitor's recently released preliminary, top-line clinical trial data for the potential use of an antibody fragment in the treatment of neovascular age-related macular degeneration (neovascular AMD). Neovascular AMD is the leading cause of blindness in people over 60 years of age.

**Conference Call and Webcast Information**

Eyetech will hold the conference call and simultaneous webcast on Thursday, May 26, 2005, at 8:30 a.m., Eastern Time. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally). A playback of the call will be available through June 1, 2005 by dialing 800-642-1687, passcode 6644652 (in the United States), or 706-645-9291, passcode 6644652 (internationally). To access the call by live webcast, please log on to the Investor Relations section of Eyetech's website at [www.eyetech.com](http://www.eyetech.com). An archived version of the webcast will be available at the same location through June 1, 2005.

**About Macugen**

Macugen is indicated in the United States and Brazil for the treatment of neovascular age-related macular degeneration and in Canada for subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD. Macugen is a pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the pathological processes that contribute to the vision loss associated with neovascular AMD.

For full prescribing information about Macugen, please visit <http://www.macugen.com>.

**About Eyetech Pharmaceuticals, Inc.**

Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. Eyetech's initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen® (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD. Macugen is also being studied for other indications including diabetic macular edema and retinal vein occlusion.

###